Press releases

25th January 2023

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models. STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors

10th January 2023

STORM Therapeutics Expands R&D Leadership Team

Matthew Fyfe joins as Senior Vice President of Therapeutics. Beth Thomas promoted to Vice President of Medicinal Chemistry.

14th December 2022

STORM Therapeutics announces closing of USD $30M Series B financing

Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias. Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification.

23rd November 2022

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

STC-15 is the first molecule specifically targeting an RNA methyltransferase to enter clinical development

20th October 2022

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3. STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022.